
Crucell | Janssen
5 days ago · Crucell joined the Janssen Pharmaceutical Companies of Johnson & Johnson in February 2011. For information on our organization please visit the Janssen Infectious …
Janssen Vaccines - Wikipedia
Janssen Vaccines, formerly Crucell, is a biotechnology company specializing in vaccines and biopharmaceutical technologies. It was formed when Johnson & Johnson acquired the Dutch …
Crucell Joins Johnson & Johnson | Johnson & Johnson Our Story
Crucell, a biopharmaceutical company specializing in vaccines and antibodies to fight infectious disease worldwide, was acquired by Johnson & Johnson. The purchase equipped Johnson & …
Crucell Holland BV - Crunchbase Company Profile & Funding
Crucell N.V. is a global biopharmaceutical company focused on research development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious …
Johnson & Johnson Acquires Vaccine Developer Crucell
Mar 8, 2011 · Johnson & Johnson (J&J) has acquired Netherlands-based biopharmaceutical company Crucell for close to $2.4 billion dollars, moving J&J prominently into the arena of …
Crucell | LinkedIn
Crucell is a global biopharmaceutical company dedicated to bringing meaningful innovation to global health.
Crucell Discovers Important New Antibody Against Influenza A
Jul 8, 2011 · Crucell is one of the major suppliers of vaccines to UNICEF and the developing world. Crucell was the first manufacturer to launch a fully-liquid pentavalent vaccine. Called …
Crucell N.V. - Leiden, Netherlands - bionity.com
Jan 5, 2015 · Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and …
Crucell and Scripps Research discover and describe broad …
Aug 10, 2012 · Crucell is a biopharmaceutical company dedicated to bringing meaningful innovation to global health. Our teams focus on the discovery, development, manufacture and …
Crucell: Biopharmaceuticals-As Human as They Get - Cell Press
Summarized under the catch-phrase “huMADE,” Crucell focuses on the development of human antibody-based therapeutics for treatment of cancer and inflammatory diseases and for the …